Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 18, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 925,000 ordinary shares of 25 pence each.
- Purchase Price: 1,343.14 pence per share.
- Treasury Shares Held: 233,622,678 shares (post-transaction).
- Shares in Issue: 5,757,754,246 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on December 18, 2006. This transaction was conducted under authority granted by shareholders at the Annual General Meeting on May 17, 2006. The acquired shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 925,000 shares by the 1,343.14 pence price.
- Confirm the impact of the 233,622,678 Treasury shares on earnings per share (EPS) calculations in subsequent reports.
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authorization.